LLY

1,061.89

+3.35%↑

JNJ

214.89

+1.63%↑

ABBV

227.07

+1.62%↑

UNH

340.22

-0.34%↓

AZN

91.58

+1.99%↑

LLY

1,061.89

+3.35%↑

JNJ

214.89

+1.63%↑

ABBV

227.07

+1.62%↑

UNH

340.22

-0.34%↓

AZN

91.58

+1.99%↑

LLY

1,061.89

+3.35%↑

JNJ

214.89

+1.63%↑

ABBV

227.07

+1.62%↑

UNH

340.22

-0.34%↓

AZN

91.58

+1.99%↑

LLY

1,061.89

+3.35%↑

JNJ

214.89

+1.63%↑

ABBV

227.07

+1.62%↑

UNH

340.22

-0.34%↓

AZN

91.58

+1.99%↑

LLY

1,061.89

+3.35%↑

JNJ

214.89

+1.63%↑

ABBV

227.07

+1.62%↑

UNH

340.22

-0.34%↓

AZN

91.58

+1.99%↑

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Avatud

4.94 5.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.7

Max

5.06

Põhinäitajad
By Trading Economics
Sissetulek	-10M -7.7M
Müük	-10M 529K
Aktsiakasum	-0.056
Kasumimarginaal	-1,463.516
Töötajad	44
EBITDA	-10M -7.7M

Turustatistika
By TradingEconomics
Turukapital	-11M 869M
Eelmine avamishind	-0.17
Eelmine sulgemishind	4.94

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2025, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13. dets 2025, 00:04 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14. dets 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14. dets 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14. dets 2025, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101M Copper Miner Alta

14. dets 2025, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Acquire Remaining 64% of Alta Copper

14. dets 2025, 17:00 UTC

Tulu

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14. dets 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13. dets 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 08:00 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 07:00 UTC

Omandamised, ülevõtmised, äriostud

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. dets 2025, 00:24 UTC

Omandamised, ülevõtmised, äriostud

Want a Piece Of SpaceX? -- Barrons.com

12. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. dets 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. dets 2025, 22:32 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 20:45 UTC

Tulu

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. dets 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. dets 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. dets 2025, 19:23 UTC

Tulu

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. dets 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. dets 2025, 18:33 UTC

Omandamised, ülevõtmised, äriostud

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. dets 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. dets 2025, 17:49 UTC

Tulu

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. dets 2025, 17:34 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.